HOME >> MEDICINE >> NEWS
Use of estrogen by postmenopausal women does not increase risk of breast cancer

CHICAGO Postmenopausal women treated with estrogen therapy for seven years did not experience an increased risk of breast cancer, according to a study in the April 12 issue of JAMA.

The Women's Health Initiative (WHI) Estrogen-Alone trial, which randomized women with prior hysterectomy to conjugated equine estrogens (CEE) or placebo, was stopped earlier than planned because of increased stroke incidence and no reduction in risk of coronary heart disease. In contrast to substantial epidemiological evidence associating exogenous (originating externally) estrogens with increased breast cancer incidence, preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports.

Marcia L. Stefanick, Ph.D., of Stanford University, Stanford, Calif., and colleagues with the WHI study, analyzed the data from the CEE-alone group of the WHI study to determine the effects of CEE on breast cancers and mammographic findings. The study included 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy who were randomized to CEE or placebo at 40 U.S. clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included. Participants received a dose of 0.625 mg/d of CEE or an identical-appearing placebo.

In an analyses of all events (n = 237 cases) occurring prior to intervention termination, after an average follow-up of 7.1 years, nonsignificant reductions were observed for invasive breast cancer (20 percent lower rate) and for total breast cancer (18 percent lower rate) in women randomized to CEE, when compared to the placebo group. The annualized rates were 0.28 (104 cases in the CEE group) and 0.34 (133 cases in the placebo group). In further analyses, fewer breast cancers with localized disease were diagnosed
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
11-Apr-2006


Page: 1 2

Related medicine news :

1. COX inhibitors may weaken protective qualities of estrogen hormone therapy
2. Study describes action of estrogen in protecting bone
3. New path from estrogen to survival in breast cancer cells described
4. High estrogen levels associated with dementia in older men
5. Ultra low-dose estrogen shown safe for post-menopausal women
6. Gabapentin cools hot flashes as well as estrogen
7. Study uncovers significant functional differences of novel estrogen receptor
8. Early estrogen exposure leads to later prostate cancer risk
9. Long-term estrogen therapy linked to breast cancer risk
10. Low estrogen levels in men linked to increased risk for hip fracture
11. Benefit of chemotherapy in breast cancer depends on estrogen-receptor status

Post Your Comments:
(Date:11/23/2014)... 24, 2014 Tbdress.com has recently ... online on Nov. 28, 2014. The special offer will provide ... Tbdress.com is one of the world’s largest women’s dresses retailers, ... colors. People can enjoy great discounts on that day: Everything ... free delivery (for orders above $89). , People can use ...
(Date:11/23/2014)... 2014 Nearly 260 testosterone lawsuits ... deep vein thrombosis and other serious cardiovascular events ... litigation (MDL) underway in the Northern District of ... documents updated on November 17th by the U.S. ... filing of 259 lawsuits against the makers of ...
(Date:11/23/2014)... Nov. 23, 2014 (HealthDay News) -- The holidays can ... because sensory overload can trigger major meltdowns, an expert ... the best of circumstances, but when you have children ... Gibbs, an occupational therapy professor at University of the ... "It,s best to let your hosts or visitors ...
(Date:11/23/2014)... 2014 This evaluation provides a ... significance, programs and manufacturing technological innovation. Then, the ... market gamers in information. In this part, the ... manufacturing value, and 2009-2014 market shares for each ... the globally and Chinese suppliers finish market of ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 SWAccessControl.com's high ... global market. Recently, the company has announced its new ... special offer on these high quality power suppliers. All ... 30% off. The special offer lasts until Dec. 20, ... many of them have been supporting it for a ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
(Date:11/22/2014)... 22, 2014  Sprout Pharmaceuticals today announced positive preliminary results ... treated with flibanserin up to 200 mg at bedtime had ... at the 20 th Annual Fall Scientific Meeting of ... in Miami . The ... Complete Response Letter and the Formal Dispute Resolution that was ...
(Date:11/22/2014)... --  Long Beach dentist , Dr. Rassouli, is now offering ... in tooth replacement because they offer the closest match to ... and preserve smiles and improve overall dental health. Dr. Rassouli ... as a part of a smile makeover or full mouth ... smile. The loss of a tooth can lead ...
(Date:11/22/2014)... Nov. 21, 2014 Research and Markets  has ... Drug Industry Report, 2014-2017" report to their offering. ... The Chinese recombinant protein drug market has been expanding ... ability and the like. During 2005-2013, sales of recombinant ... a CAGR of 19.1%, and it is projected that ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
Cached News: